Sagimet Biosciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Sagimet Biosciences şirketinin kazançları yıllık ortalama -16.5% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.1% oranında artan oldu. Gelirler yıllık ortalama 50.2% oranında artan oldu.

Anahtar bilgiler

-16.5%

Kazanç büyüme oranı

64.8%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	50.2%
Özkaynak getirisi	-22.0%
Net Marj	n/a
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

Sagimet: More Than Just A MASH Drug Development Biotech

Nov 14

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat

Oct 18

Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide

Jul 31

Companies Like Sagimet Biosciences (NASDAQ:SGMT) Are In A Position To Invest In Growth

May 31

Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity

Apr 26

Sagimet: Additional Upside Possible After Latest NASH Data Release

Jan 24

Gelir ve Gider Dağılımı

Sagimet Biosciences nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGM:SGMT Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	0	-38	16	30
30 Jun 24	2	-29	16	22
31 Mar 24	2	-28	14	21
31 Dec 23	2	-28	13	20
30 Sep 23	2	-27	11	20
30 Jun 23	0	-28	7	22
31 Mar 23	0	-28	6	24
31 Dec 22	0	-30	6	25
31 Dec 21	0	-24	4	19
31 Dec 20	0	-11	3	8

Kaliteli Kazançlar: SGMT şu anda kârlı değil.

Büyüyen Kar Marjı: SGMT şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: SGMT kârlı değildir ve zararlar son 5 yılda yılda 16.5% oranında artmıştır.

Büyüme Hızlandırma: SGMT 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: SGMT kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: SGMT hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -21.98% ) sahiptir.

Sagimet Biosciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Recent updates

Sagimet Biosciences Inc. Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - the Liver Meeting 2024

Sagimet: More Than Just A MASH Drug Development Biotech

Sagimet Biosciences Announces Successful Completion of End-Of-Phase 2 Interactions with Fda on the Development of Denifanstat for Mash

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Sagimet Biosciences Inc. Receives U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for Asc40

Sagimet Biosciences Inc. Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Sagimet Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Sagimet Biosciences Inc. Announces Appointment of Board of Directors

Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide

Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell 3000 Index

Sagimet Biosciences Inc. Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

Companies Like Sagimet Biosciences (NASDAQ:SGMT) Are In A Position To Invest In Growth

Sagimet Biosciences Inc. Announces Appointment of Thierry Chauche as Chief Financial Officer

Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity

Sagimet Biosciences Inc., Annual General Meeting, Jun 05, 2024

Less than half of directors are independent

CEO, President & Director recently bought US$64k worth of stock

Sagimet Biosciences Inc. Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

Sagimet Biosciences Inc. Announces Board Changes

Sagimet Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $112.5 million.

Sagimet Biosciences Inc. has filed a Follow-on Equity Offering.

Sagimet: Additional Upside Possible After Latest NASH Data Release

Sagimet Biosciences Inc. has filed a Follow-on Equity Offering.

Sagimet Biosciences Announces Positive Topline Results from Phase 2B Fascinate-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 Nash

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

New major risk - Share price stability

New minor risk - Market cap size

Sagimet Biosciences Inc. Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

Sagimet Biosciences Inc. Appoints Anthony Rimac as Principal Financial Officer and Principal Accounting Officer, Effective August 1, 2023

Independent Director recently bought US$750k worth of stock

Sagimet Biosciences Inc. has completed an IPO in the amount of $85 million.

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin